The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update.

ABSTRACT:

Introduction

Biomarkers for Alzheimer's disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD neuropathologies; for this, neuropathologic examinations and annotated tissue samples are essential.

Methods

We conducted clinicopathologic correlation for the first 100 Alzheimer's Disease Neuroimaging Initiative (ADNI) Neuropathology Core (NPC) cases.

Results

Clinical syndromes in this cohort showed 95% sensitivity and 79% specificity for predicting high/intermediate ADNC, a 21% false positive rate, and a ∼44% false negative rate. In addition, 60% with high/intermediate ADNC harbored additional potentially dementing co-pathologies.<

SUBMITTER: Perrin RJ 

PROVIDER: S-EPMC11567814 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature